News

https://doi.org/10.1016/j.actbio.2019.09.002                                                            Abstract By the appropriate selection of functional peptides and proper accommodation sites, we have generated a set of multifunctional proteins that combine selectivity for CXCR4+ cell binding and relevant endosomal escape capabilities linked to the viral peptide HA2. In particular, the construct T22-GFP-HA2-H6 forms nanoparticles that upon administration in mouse models of human, CXCR4+ colorectal cancer, accumulates in primary tumor at levels significantly higher than the parental T22-GFP-H6 HA2-lacking version. The in vivo application of a CXCR4 antagonist has confirmed the prevalence of the CXCR4+tumor tissue selectivity over unspecific cell penetration, upon system

https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201900849   Abstract Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44‐targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.                

ARTICLE| VOLUME 28, ISSUE 2, P352-367.E9, JULY 09, 2019 Covadonga Vara; Andreu Paytuví-Gallart ; Yasmina Cuartero ;Paul D. Waters; Marc A. Marti-Renom; Aurora Ruiz-Herrera Open Access DOI: https://doi.org/10.1016/j.celrep.2019.06.037                                                                                                                         https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30803-4 Summary Mammalian gametogenesis involves dramatic and tightly regulated chromatin remodeling, whose regulatory pathways remain largely unexplored. Here, we generate a comprehensive high-resolution structural and functional atlas of mouse spermatogenesis by combining in situ chromosome conformation capture sequencing (Hi-C), RNA sequencing (RNA-seq), and chromatin immunopr

http://www.haematologica.org/content/early/2019/06/25/haematol.2018.211490.article-info Aïda Falgàs, Victor Pallarès, Ugutz Unzueta, María Virtudes Céspedes, Irene Arroyo-Solera, María José Moreno, Alberto Gallardo, María Antonia Mangues, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Ramon Mangues, Isolda Casanova Haematologica June 2019 : haematol.2018.211490; Doi:10.3324/haematol.2018.211490 Abstract One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4+) associates with lower overall and disease-free survival. Nanomedicine pursues active targeting to selectively deliver antitumor agents to cancer

https://onlinelibrary.wiley.com/doi/full/10.1002/open.201900038 Abstract Oligonucleotide‐protein conjugates have important applications in biomedicine. Simple and efficient methods are described for the preparation of these conjugates. Specifically, we describe a new method in which a bifunctional linker is attached to thiol‐oligonucleotide to generate a reactive intermediate that is used to link to the protein. Having similar conjugation efficacy compared with the classical method in which the bifunctional linker is attached first to the protein, this new approach produces significantly more active conjugates with higher batch to batch reproducibility. In a second approach, direct conjugation is proposed using oligonucleotides carrying carboxyl groups. These methodologies have been ap

Demà, 5 de Juliol, al voltant de les 12:00 i fins les 13:30, l’alumnat del curs d’estiu “Què podem fer per reduir la resistència als antibiòtics?“, impartit pel grup de Genètica Molecular i Patogènesi Bacteriana, exposarà part del treball divulgatiu que han preparat. Es tracta de cartells/murals que tenen com a objectiu difondre a la societat l’ús correcte dels antibiòtics i així evitar-ne les resistències.  L’acte es farà al pati del edifici MRB i hi sou tots convidats.

  https://www.uab.cat/web/programa-argo/programa-argo-estudiants/estudiants/cursos-estiu/Que-podem-fer-per-reduir-la-resistencia-als-antibiotics-1345783047637.html Què podem fer per reduir la resistència als antibiòtics?   Adreçat a: alumnes de 3r i 4t d’ESO, Batxillerat i Cicles Formatius. Calendari: de l'1 al 5 de juliol de 2019. Horari: de 9:30 a 14h., amb una pausa de 30 minuts. Dilluns 1 de juliol es convocarà l'alumnat a les 8:30h. Professorat: Xavier Coves Lozano, Isidre Gibert González, Pol Huedo Moreno i Daniel Yero Corona. Lloc de realització: Institut de Biotecnologia i de Biomedicina, IBB i Aules d’informàtica de la Facultat de Biociències. Instruccions de registre i d'inscripció Accès a la matrícula dels cursos de la setmana de l'1 al 5 de juliol

Abstract Amyloids have been exploited to build amazing bioactive materials. In most cases, short synthetic peptides constitute the functional components of such materials. The controlled assembly of globular proteins into active amyloid nanofibrils is still challenging, because the formation of amyloids implies a conformational conversion towards a β-sheet-rich structure, with a concomitant loss of the native fold and the inactivation of the protein. There is, however, a remarkable exception to this rule: yeast prions. They are singular proteins able to switch between a soluble and an amyloid state. In both states, the structure of their globular domains remains essentially intact. The transit between these two conformations is encoded in prion domains (PrDs): long and disordered sequ

L’esdeveniment reuneix 44 investigadors capdavanters en l’estudi de noves eines per al tractament i l’evolució de malalties neurodegeneratives que van rebre finançament de l’edició de 2013. Al llarg del matí s’hi faran diverses sessions de treball i taules rodones en què s’hi presentaran les recerques realitzades. Entre aquestes, hi ha dues liderades per investigadors de la UAB: Salvador Ventura Zamora, investigador de l’Institut de Biotecnologia i Biomedicina (IBB) i del Departament de Bioquímica i de Biologia Molecular, exposarà la investigació que li ha permès identificar una molècula que atura i reverteix la neurodegeneració que provoca la malaltia de Parkinson. La molècula identificada interromp la formació de fibres amiloides d'alfa-sinucleïna, el procés que desencadena el Parkins